Chenpon’s First Reservoir-Type DPI Product Pingchuan® Approved for Marketing in China
A Major Commercial Milestone for Chenpon’s Proprietary DPI Platform
Chenpon Pharmaceutical is pleased to announce that Budesonide and Formoterol Fumarate Powder for Inhalation (II), marketed under the brand name Pingchuan®, developed by its subsidiary Shanghai Xin Huanghe Pharmaceutical Co., Ltd., has been approved for marketing in China.
Pingchuan® is the first domestically developed generic dry powder inhalation product of its kind approved in China, providing a new treatment option for patients with asthma and chronic obstructive pulmonary disease (COPD).
More Than a Decade of Commitment to DPI Development
The Pingchuan® program was initiated in 2013. Over more than a decade of development, Chenpon has built integrated capabilities across formulation and powder engineering, inhaler design, airflow dynamics, analytical evaluation, clinical development, scale-up manufacturing and regulatory registration.
Dry powder inhalers are highly complex drug-device combination products, requiring close integration between formulation characteristics, device engineering, airflow performance and manufacturing processes. Through sustained investment in this field, Chenpon has established its proprietary reservoir-type multidose DPI platform and an expanding intellectual property portfolio covering inhaler technologies.
Designed with Both Performance and Patients in Mind
Clinical studies demonstrated bioequivalence between Pingchuan® and the reference product, while a multicenter randomized double-blind comparative study demonstrated non-inferior efficacy and comparable safety. Human factors studies were also conducted to evaluate the usability of the inhaler in real-world patient operation.
The proprietary multidose reservoir DPI incorporates several patient-oriented design features, including a more precise dose-counter display, remaining-dose alerts, audible confirmation of correct operation, and an ergonomic structure designed to support intuitive use.
From One Product to a Respiratory Drug-Delivery Platform
The approval of Pingchuan® represents more than the launch of a single product. It marks an important commercialization milestone for Chenpon’s proprietary reservoir-type DPI technology platform.
Building on this platform, Chenpon will continue to advance complex inhalation formulations and innovative respiratory drug-delivery programs, while further strengthening its integrated capabilities in DPI formulation development, device engineering, clinical development, regulatory registration and commercial manufacturing.
Looking ahead, Chenpon will also continue exploring international registration, licensing, supply and technology collaboration opportunities, with the goal of bringing high-quality inhalation solutions developed in China to patients worldwide.
Breathing Solutions. Access Revolution.